NovaBridge Advances Gastric Cancer Candidate into Phase 2 Trial
Event summary
- NovaBridge initiated a global, randomized Phase 2 study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX6 for 1L metastatic gastric cancer.
- Phase 1b data showed a 75% objective response rate (ORR), a median progression-free survival (mPFS) of 16.9 months, and an 82% 6-month landmark PFS.
- The Phase 2 study aims to enroll approximately 180 patients and expects top-line results in 2027.
- Givastomig is being jointly developed with ABL Bio, with NovaBridge holding worldwide rights excluding Greater China and South Korea.
The big picture
The gastric cancer market represents a significant unmet need and a $12 billion opportunity by 2030, driving intense competition for effective therapies. NovaBridge’s givastomig, with its bispecific antibody design targeting CLDN18.2 and activating T cells, aims to address this need, but faces challenges in demonstrating superior efficacy and safety compared to existing immunotherapies and chemotherapy regimens. The Phase 2 trial results will be a crucial inflection point for the company’s valuation and future prospects.
What we're watching
- Clinical Efficacy
- The Phase 2 trial’s results will be critical in validating the Phase 1b data and determining if givastomig can meaningfully improve patient outcomes compared to standard of care, particularly given the competitive landscape in gastric cancer treatment.
- Regulatory Pathway
- The success of the Phase 2 trial will heavily influence NovaBridge’s ability to secure regulatory approval, and the FDA’s assessment of the combination therapy’s safety profile will be a key factor in its potential market adoption.
- Partner Dynamics
- The ongoing collaboration with ABL Bio will be important to monitor, as shared development costs and rights could impact NovaBridge’s profitability and future strategic options.
Related topics